PTCT 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-07-30

• During the quarter ended June 30, 2026, we initiated a Phase 1 study of PTC612, our oral NLRP3 inhibitor, and completed several of the single and multiple ascending dose treatment cohorts. Notably, this healthy volunteer study includes a cohort of individuals with obesity and cardiovascular disease,…

• the third quarter of 2026. The PTC844 study will be a 12-week pharmacokinetics and pharmacodynamics study in which we will assess treatment effect on biomarkers related to T-cell and B-cell immunity. We expect that the results of this study will help inform the ultimate target indications for PTC844…

• and 16.6666% of the Royalty from and after such time as the 2020 Assigned Royalty Cap has been met. As a result of the sale, Royalty Pharma owns 100% of the Royalty and we own 0% of the Royalty.

• In November 2024, we entered into the Novartis Agreement relating to our votoplam HD program which includes related molecules. Novartis is responsible for all other development of licensed compounds and licensed products and the manufacture and commercialization of licensed compounds and licensed pr…

• In June 2026, we issued $550.0 million aggregate principal amount of 0% convertible senior notes due 2031, or the 2031 Convertible Notes, which reflects the exercise in full by the initial purchasers of their option to purchase up to an additional $50.0 million in aggregate principal amount of the 2…

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• In November 2024, we entered into the Novartis Agreement relating to our votoplam HD program which includes related molecules. Novartis is responsible for all other development of licensed compounds and licensed products and the manufacture and commercialization of licensed compounds and licensed pr…

• $1.9 billion in development, regulatory and sales milestones, a 40% share of U.S. profits and losses, and tiered double-digit royalties on ex-U.S. sales.

• As of March 31, 2026, we had an accumulated deficit of $2,967.0 million. We had a net loss of $2.8 million and net income of $866.6 million for the three months ended March 31, 2026 and 2025, respectively.

• With respect to our outstanding 1.50% convertible senior notes due September 15, 2026, or the 2026 Convertible Notes, cash interest payments were payable on a semi-annual basis in arrears, which will require remaining funding of $2.2 million. These notes are currently convertible and will mature and…

• We also have certain significant contractual obligations and commercial commitments that require funding and we have disclosed these items under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Funding Obligations” in our 2025 Annual Report. There we…

相对上期新增的文字 · 来源:10-Q · 2026-07-30

• Michael Schmertzler (Director) (by Section Six Partners, L.P., of which Mr. Schmertzler is a general partner and limited partner)

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• Until December 31, 2026, or until such earlier date upon which all transactions are completed

• Until March 31, 2027, or until such earlier date upon which all transactions are completed

• This trading arrangement related to 35,500 shares of Company common stock and had a scheduled expiration date of March 31, 2026, or such earlier date upon which all transactions were completed.